| Literature DB >> 32579906 |
Ho Yeung Lam1, Tsz Sum Lam2, Chi Hong Wong2, Wing Hang Lam2, Chi Mei Emily Leung2, Ka Wing Albert Au2, Chau Kuen Yonnie Lam2, Tin Wai Winnie Lau2, Yung Wai Desmond Chan2, Ka Hing Wong2, Shuk Kwan Chuang2.
Abstract
BACKGROUND: Hong Kong, a Special Administrative Region of China, recorded its first confirmed coronavirus disease 2019 (COVID-19) case on 23 January 2020. We reviewed the case epidemiology and the various public health measures implemented from January to May 2020.Entities:
Keywords: COVID-19; Contact tracing; Enhanced surveillance; Hong Kong; Novel coronavirus; Public health intervention; Quarantine; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32579906 PMCID: PMC7306206 DOI: 10.1016/j.ijid.2020.06.057
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Epidemiological and clinical profiles of the 1084 confirmed COVID-19 cases reported in Hong Kong
| Imported case( | Linked local case | Unlinked local case | Possibly imported case | Total( | ||
|---|---|---|---|---|---|---|
| Total | 657 (60.6%) | 250 (23.1%) | 69 (6.4%) | 108 (10%) | 1084 | |
| Age (years) | ||||||
| 0–14 | 29 (4.4%) | 9 (3.6%) | 0 (0%) | 1 (0.9%) | 39 (3.6%) | <0.00001 |
| 15–24 | 264 (40.2%) | 17 (6.8%) | 1 (1.4%) | 7 (6.5%) | 289 (26.7%) | |
| 25–44 | 181 (27.5%) | 122 (48.8%) | 35 (50.7%) | 57 (52.8%) | 395 (36.4%) | |
| 45–64 | 142 (21.6%) | 73 (29.2%) | 25 (36.2%) | 36 (33.3%) | 276 (25.5%) | |
| 65+ | 41 (6.2%) | 29 (11.6%) | 8 (11.6%) | 7 (6.5%) | 85 (7.8%) | |
| Sex | ||||||
| Male | 362 (55.1%) | 123 (49.2%) | 42 (60.9%) | 61 (56.5%) | 588 (54.2%) | 0.241 |
| Female | 295 (44.9%) | 127 (50.8%) | 27 (39.1%) | 47 (43.5%) | 496 (45.8%) | |
| Condition | ||||||
| Ever critical or serious/death | 21 (3.2%) | 14 (5.6%) | 16 (23.2%) | 2 (1.9%) | 53 (4.9%) | <0.00001 |
| Stable | 636 (96.8%) | 236 (94.4%) | 53 (76.8%) | 106 (98.1%) | 1031 (95.1%) | |
| Mode of case identification | ||||||
| Active notification by medical practitioners | 236 (35.9%) | 48 (19.2%) | 2 (2.9%) | 50 (46.3%) | 336 (31%) | <0.00001 |
| Contact tracing by CHP | 72 (11%) | 132 (52.8%) | 5 (7.2%) | 5 (4.6%) | 214 (19.7%) | |
| Enhanced laboratory surveillance in public hospitals | 6 (0.9%) | 15 (6%) | 21 (30.4%) | 7 (6.5%) | 49 (4.5%) | |
| Enhanced surveillance at emergency departments, GOPCs, and private sector | 71 (10.8%) | 55 (22%) | 41 (59.4%) | 41 (38%) | 208 (19.2%) | |
| Enhanced surveillance for returning travellers | 272 (41.4%) | 0 (0%) | 0 (0%) | 5 (4.6%) | 277 (25.6%) | |
| Average onset-to-admission interval (days) | 2.6 | 3.6 | 6.3 | 4.2 | 3.2 | <0.00001 |
| Average hospital length of stay for discharged cases (days) | 20.4 | 24.1 | 23.6 | 21.8 | 21.6 | 0.00006604 |
CHP, Centre for Health Protection; GOPC, general outpatient clinic.
Chi-square test.
Welch F-test.
Key summary of cases by phases of the COVID-19 epidemic
| Phase one | Phase two(4 Feb to 3 Mar 2020) | Phase three(4 Mar to 19 Apr 2020) | Phase four(20 Apr to 31 May 2020) | Total | ||
|---|---|---|---|---|---|---|
| Total | 15 (1.4%) | 85 (7.8%) | 925 (85.3%) | 59 (5.4%) | 1084 | |
| Case classification | ||||||
| Imported case | 12 (80%) | 11 (12.9%) | 581 (62.8%) | 53 (89.8%) | 657 (60.6%) | <0.00001 |
| Linked local case | 2 (13.3%) | 49 (57.6%) | 196 (21.2%) | 3 (5.1%) | 250 (23.1%) | |
| Unlinked local case | 0 (0%) | 19 (22.4%) | 48 (5.2%) | 2 (3.4%) | 69 (6.4%) | |
| Possibly imported case | 1 (6.7%) | 6 (7.1%) | 100 (10.8%) | 1 (1.7%) | 108 (10%) | |
| Mode of case identification | ||||||
| Active notification by medical practitioners | 10 (66.7%) | 0 (0%) | 322 (34.8%) | 4 (6.8%) | 336 (31%) | <0.00001 |
| Contact tracing by CHP | 3 (20%) | 49 (57.6%) | 157 (17%) | 5 (8.5%) | 214 (19.7%) | |
| Enhanced laboratory surveillance in public hospitals | 2 (13.3%) | 32 (37.6%) | 14 (1.5%) | 1 (1.7%) | 49 (4.5%) | |
| Enhanced surveillance at emergency departments, GOPCs, and private sector | 0 (0%) | 4 (4.7%) | 202 (21.8%) | 2 (3.4%) | 208 (19.2%) | |
| Enhanced surveillance for returning travellers | 0 (0%) | 0 (0%) | 230 (24.9%) | 47 (79.7%) | 277 (25.6%) | |
| Age (years) | ||||||
| 0–14 | 0 (0%) | 0 (0%) | 27 (2.9%) | 12 (20.3%) | 39 (3.6%) | <0.00001 |
| 15–24 | 0 (0%) | 6 (7.1%) | 274 (29.6%) | 9 (15.3%) | 289 (26.7%) | |
| 25–44 | 3 (20%) | 15 (17.6%) | 355 (38.4%) | 22 (37.3%) | 395 (36.4%) | |
| 45–64 | 6 (40%) | 36 (42.4%) | 223 (24.1%) | 11 (18.6%) | 276 (25.5%) | |
| 65+ | 6 (40%) | 28 (32.9%) | 46 (5%) | 5 (8.5%) | 85 (7.8%) | |
| Sex | ||||||
| Male | 9 (60%) | 40 (47.1%) | 502 (54.3%) | 37 (62.7%) | 588 (54.2%) | 0. 299 |
| Female | 6 (40%) | 45 (52.9%) | 423 (45.7%) | 22 (37.3%) | 496 (45.8%) | |
| Symptoms | ||||||
| Symptomatic | 15 (100%) | 80 (94.1%) | 744 (80.4%) | 20 (33.9%) | 859 (79.2%) | <0.00001 |
| Asymptomatic | 0 (0%) | 5 (5.9%) | 181 (19.6%) | 39 (66.1%) | 225 (20.8%) | |
| Average daily number of COVID-19 viral tests performed | 161 | 990 | 2283 | 2245 | 1556 | NA |
CHP, Centre for Health Protection; GOPC, general outpatient clinic; NA, not applicable.
Chi-square test